Coya Therapeutics (NASDAQ: COYA) outlines $46.8M cash and ALSTARS Phase 2 data timing

Rhea-AI Filing Summary

Coya Therapeutics, Inc. filed a current report describing a stockholder letter that updates its financial position and key clinical milestone timing. The company reported an unaudited cash balance of $46.8 million as of December 31, 2025, and stated it has a projected cash runway into the second half of 2027, indicating it currently expects to fund operations for an extended period. Coya also noted that it expects a topline data readout from its ongoing ALSTARS Phase 2 trial in the first quarter of 2027, giving investors a timeframe for when important clinical results may become available.

Insights

Biotech equity analyst

Coya highlights cash runway into 2H 2027 and a key Phase 2 data milestone in early 2027.

Coya Therapeutics reports an unaudited cash balance of $46.8 million as of December 31, 2025, alongside a projected cash runway into the second half of 2027. For a clinical-stage biotech, this suggests current resources are expected to support operations through several more years of development activity.

The company also sets expectations for a topline data readout from its ALSTARS Phase 2 trial in the first quarter of 2027. This anchors a future clinical catalyst date that may be important to how the program is evaluated once results are available. Actual impact on the business will depend on the eventual trial outcomes and any future updates the company provides.

false 0001835022 0001835022 2026-01-20 2026-01-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 20, 2026

Coya Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-41583		85-4017781
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

5850 San Felipe St., Suite 500
Houston, Texas				77057
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 800 587-8170

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		COYA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 20, 2026, Coya Therapeutics, Inc. (the “Company”) issued a letter to its stockholders wherein it announced its cash balance as of December 31, 2025 was $46.8 million (unaudited) with projected cash runway into the second half of 2027, and that the Company expects a topline data readout from its current ALSTARS Phase 2 trial in the first quarter of 2027.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						COYA THERAPEUTICS, INC.
Date: January 20, 2026				By:		/s/ Arun Swaminathan Ph.D.
						Arun Swaminathan Ph.D.
						Chief Executive Officer

FAQ

What did Coya Therapeutics (COYA) disclose about its cash position?

Coya Therapeutics reported an unaudited cash balance of $46.8 million as of December 31, 2025 in its stockholder letter.

How long does Coya Therapeutics (COYA) project its cash runway will last?

The company stated that its projected cash runway extends into the second half of 2027.

What clinical milestone timing did Coya Therapeutics (COYA) provide?

Coya expects a topline data readout from its current ALSTARS Phase 2 trial in the first quarter of 2027.

What is the purpose of this Coya Therapeutics (COYA) 8-K filing?

The filing describes a letter to stockholders in which Coya updates its cash balance, projected cash runway, and the expected timing of ALSTARS Phase 2 topline data.

Is the reported Coya Therapeutics (COYA) cash balance audited?

No. The company stated that the cash balance of $46.8 million as of December 31, 2025 is unaudited.